Ep 212 PECARN Febrile Young Infant Prediction Tool: When To Safely Forgo LP and Empiric Antibiotics

January 27, 2026

AI Summary

5 min read

The Febrile Infant Prediction Tool: Safely Deferring Lumbar Punctures in the First Month of Life

For decades, the standard approach to febrile young infants was straightforward: perform a lumbar puncture, start empiric antibiotics, and admit to hospital. That strategy prevented missed cases of bacterial meningitis, but it also subjected large numbers of infants to invasive procedures, unnecessary antibiotics, and hospitalization-related harm. Now, a major new JAMA pooled cohort study—the largest ever analysis of febrile infants zero to twenty-eight days of age—has refined our ability to identify which infants can safely forgo lumbar puncture and empiric antibiotics, without sacrificing safety.

The Shift from Serious to Invasive Bacterial Infection

Continue reading the full summary in the app — free to try.

Read Full Summary →

Free • No credit card required

Listen to Audio Summary Open in App

Never miss an episode of Emergency Medicine Cases

Get every new episode summarized in your inbox — free, ~5 minutes to read.

No spam. Unsubscribe anytime.

What you'll learn

1 (01:32) **Episode Introduction & Historical Context** - Host Anton Hellman frames the shift from routine LP/antibiotics for febrile young infants toward risk stratification and shared decision-making.
2 (04:14) **Guest Introductions: Dr. Nate Cooperman & Dr. Brett Burstein** - Cooperman (PECARN founder, lead author of original febrile infant rule) and Burstein (first author of the 2025 JAMA study) join the discussion.
3 (09:04) **PECARN Prediction Tool: Inclusion & Exclusion Criteria** - The tool is designed for well-appearing febrile infants 0-60 days who present a diagnostic challenge.
4 (13:31) **The Updated PECARN Rule: Three Simple Tests** - Identifies low-risk infants using a negative urinalysis, procalcitonin <0.5, and absolute neutrophil count <4,000.
5 (15:35) **Urinalysis: Collection & Interpretation** - Practical guidance on obtaining and reading the urine test.
6 (20:57) **HSV: When to Suspect & Exclude from the Rule** - Key historical and exam features for HSV encephalitis, which the PECARN tool does not address.
7 (27:04) **Pitfalls in Assessing Febrile Infants** - Common errors that undermine the workup.

+ Full timestamped outline available in the app

Show Notes

If you’ve been practicing EM for more than a decade, your approach to the febrile young infant has (appropriately) evolved. For years, the default was LP + empiric antibiotics + admission for almost everyone. That approach prevented missing meningitis, but at the cost of a lot of harm: invasive testing, unnecessary antibiotics, and hospitalization-related complications. The modern approach is a paradigm shift toward risk stratification, biomarkers, and shared decision-making, while still respecting one immutable truth: Missing neonatal bacterial meningitis can be catastrophic. This episode revisits the framework from a prior EM Cases episode and updates it with a landmark study that directly informs how far we can safely go—especially in the 0–28 day group, with the father of multiple well-known PECARN rules Dr. Nathan Kuppermann and lead author Dr. Brett Burstein...